serine and exenatide

serine has been researched along with exenatide in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cignarelli, A; De Stefano, F; Giorgino, F; Labarbuta, R; Laviola, L; Leonardini, A; Marchetti, P; Melchiorre, M; Natalicchio, A; Orlando, MR; Perrini, S	1
Donnelly, D; Mann, RJ; Nasr, NE; Paci, E; Sinfield, JK	1

Other Studies

2 other study(ies) available for serine and exenatide

Article	Year
Exendin-4 prevents c-Jun N-terminal protein kinase activation by tumor necrosis factor-alpha (TNFalpha) and inhibits TNFalpha-induced apoptosis in insulin-secreting cells. Endocrinology, 2010, Volume: 151, Issue:5 Topics: Animals; Apoptosis; Cell Line, Tumor; Enzyme Activation; Exenatide; Humans; Hypoglycemic Agents; I-kappa B Proteins; Immunoblotting; Insulin Receptor Substrate Proteins; Insulin-Secreting Cells; Isoquinolines; JNK Mitogen-Activated Protein Kinases; NF-KappaB Inhibitor alpha; Peptides; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Serine; Sulfonamides; Time Factors; Tumor Necrosis Factor-alpha; Venoms	2010
The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4. British journal of pharmacology, 2010, Volume: 160, Issue:8 Topics: Animals; Aspartic Acid; Binding Sites; Binding, Competitive; Cell Line; Exenatide; Glucagon-Like Peptide-1 Receptor; Glutamic Acid; Humans; Hydrogen Bonding; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Mutagenesis, Site-Directed; Peptides; Protein Conformation; Protein Structure, Tertiary; Radioligand Assay; Rats; Receptors, Glucagon; Recombinant Proteins; Serine; Structure-Activity Relationship; Transfection; Venoms	2010

Article

Year

Exendin-4 prevents c-Jun N-terminal protein kinase activation by tumor necrosis factor-alpha (TNFalpha) and inhibits TNFalpha-induced apoptosis in insulin-secreting cells.

Endocrinology, 2010, Volume: 151, Issue:5

Topics: Animals; Apoptosis; Cell Line, Tumor; Enzyme Activation; Exenatide; Humans; Hypoglycemic Agents; I-kappa B Proteins; Immunoblotting; Insulin Receptor Substrate Proteins; Insulin-Secreting Cells; Isoquinolines; JNK Mitogen-Activated Protein Kinases; NF-KappaB Inhibitor alpha; Peptides; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Serine; Sulfonamides; Time Factors; Tumor Necrosis Factor-alpha; Venoms

2010

The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.

British journal of pharmacology, 2010, Volume: 160, Issue:8

Topics: Animals; Aspartic Acid; Binding Sites; Binding, Competitive; Cell Line; Exenatide; Glucagon-Like Peptide-1 Receptor; Glutamic Acid; Humans; Hydrogen Bonding; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Mutagenesis, Site-Directed; Peptides; Protein Conformation; Protein Structure, Tertiary; Radioligand Assay; Rats; Receptors, Glucagon; Recombinant Proteins; Serine; Structure-Activity Relationship; Transfection; Venoms

2010